NewAmsterdam Pharma Company NV (NASDAQ: NAMS) kicked off on Monday, up 8.60% from the previous trading day, before settling in for the closing price of $15.12. Over the past 52 weeks, NAMS has traded in a range of $14.06-$27.29.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Healthcare Sector giant saw their annual sales surged by 34.27% over the last five years. While this was happening, its average annual earnings per share was recorded 29.95%. With a float of $61.06 million, this company’s outstanding shares have now reached $108.06 million.
The firm has a total of 68 workers. Let’s measure their productivity. In terms of profitability, gross margin is 99.96%, operating margin of -370.98%, and the pretax margin is -512.33%.
NewAmsterdam Pharma Company NV (NAMS) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of NewAmsterdam Pharma Company NV is 44.40%, while institutional ownership is 48.02%. The most recent insider transaction that took place on Apr 11 ’25, was worth 21,669,878. Before that another transaction happened on Mar 26 ’25, when Company’s Director bought 1,135 for $22.49, making the entire transaction worth $25,521. This insider now owns 3,013,569 shares in total.
NewAmsterdam Pharma Company NV (NAMS) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.42 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 29.95% per share during the next fiscal year.
NewAmsterdam Pharma Company NV (NASDAQ: NAMS) Trading Performance Indicators
Take a look at NewAmsterdam Pharma Company NV’s (NAMS) current performance indicators. Last quarter, stock had a quick ratio of 8.08. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 39.58.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.60, a number that is poised to hit -0.50 in the next quarter and is forecasted to reach -1.84 in one year’s time.
Technical Analysis of NewAmsterdam Pharma Company NV (NAMS)
Analysing the last 5-days average volume posted by the [NewAmsterdam Pharma Company NV, NAMS], we can find that recorded value of 1.13 million was better than the volume posted last year of 0.98 million. As of the previous 9 days, the stock’s Stochastic %D was 26.13%. Additionally, its Average True Range was 1.57.
During the past 100 days, NewAmsterdam Pharma Company NV’s (NAMS) raw stochastic average was set at 17.84%, which indicates a significant decrease from 25.43% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 84.05% in the past 14 days, which was higher than the 82.65% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $20.42, while its 200-day Moving Average is $20.01. Now, the first resistance to watch is $17.01. This is followed by the second major resistance level at $17.59. The third major resistance level sits at $18.64. If the price goes on to break the first support level at $15.38, it is likely to go to the next support level at $14.33. Now, if the price goes above the second support level, the third support stands at $13.75.
NewAmsterdam Pharma Company NV (NASDAQ: NAMS) Key Stats
The company with the Market Capitalisation of 1.80 billion has total of 109,818K Shares Outstanding. Its annual sales at the moment are 45,560 K in contrast with the sum of -241,600 K annual income. Company’s last quarter sales were recorded 12,770 K and last quarter income was -92,180 K.
